Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.39 |
| ▸ | CASP3 | P42574 | 3/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | CPB1 | P15086 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2849323 | 0.86 | CA1 (0.43) | KLK7KLK5CA1CA2PTGER4 | |
| SCHEMBL2845511 | 0.83 | KLK7 (0.44) | KLK7KLK5PTGER4CASP3 | |
| SCHEMBL2849324 | 0.82 | PTGER4 (0.47) | KLK7KLK5CA1CA2PTGER4 | |
| SCHEMBL2841937 | 0.82 | KLK7 (0.44) | KLK7KLK5CA1CA2PTGER4 | |
| SCHEMBL3625983 | 0.81 | KLK7 (0.45) | KLK7KLK5CA1CA2PTGER4 | |
| SCHEMBL2843551 | 0.81 | PTGER4 (0.46) | KLK7KLK5CA1CA2PTGER4 | |
| SCHEMBL2842850 | 0.80 | KLK7 (0.44) | KLK7KLK5CA1CA2PTGER4 | |
| SCHEMBL2845514 | 0.80 | CTSS (0.48) | KLK7KLK5PTGER4CASP3 | |
| SCHEMBL2845533 | 0.80 | CTSS (0.48) | KLK7KLK5PTGER4CASP3 | |
| SCHEMBL2845439 | 0.79 | KLK7 (0.44) | KLK7KLK5CA1CA2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216803-A1 | ORNITHINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-08-26 | — | — | US | claimed |
| EP-2141147-A1 | ORNITHINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-01-06 | — | — | EP | claimed |
| US-20100216803-A1 | ORNITHINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-2141147-A1 | ORNITHINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216803-A1 | ORNITHINE DERIVATIVE | PTGER4, OXER1, ODC1 | KLK7 2470/4885KLK5 1391/4885CA1 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.